EphA4 is a prognostic factor in gastric cancer

Background: Erythropoietin-producing hepatocellular (Eph) receptor, consisting of a family of receptor tyrosine kinases, plays critical roles in tumour development and is considered an attractive target for cancer therapy. Methods: Tumour samples were obtained from 222 patients with gastric adenocarcinoma who underwent gastrectomy. The expressions of EphA2, EphA4, and ephrinA1 were evaluated immunohistochemically. Results: High expressions of EphA2, EphA4, and ephrinA1 significantly correlated with variables related to tumour progression, including the depth of invasion, metastatic lymph nodes, pathological stage, and distant metastasis or recurrent disease. High expressions of EphA2, EphA4, and ephrinA1 were significantly associated with poorer disease-specific survival (DSS; p
Source: BMC Clinical Pathology - Latest articles - Category: Pathology Authors: Source Type: research

Related Links:

Splenic metastasis is known to occur at the terminal stage of cancer. While peritoneal dissemination is the most frequent recurrence of gastric cancer, metastasis to the spleen from gastric cancer is very rare. Splenectomy is currently the most effective probable treatment for solitary splenic metastasis of gastric cancer; it provides a good patient prognosis. However, careful consideration of surgical indications is required, as splenic metastasis is typically accompanied by multi-organ metastasis and dissemination. One of the main cancer treatment methods is the “wait-and-see” approach using chemotherapy. In ...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurposeTo investigate the clinicopathological features and survival outcomes between young and old patients with gastric cancer (GC), and further determine the role of young age in the prognosis of GC.MethodsPatients with stage I –III gastric adenocarcinomas undergoing curative surgery were enrolled, divided into young (aged 18–49 years, YG), middle-aged (50–59 years, MG), and old (≥ 60 years, OG) groups. Exclusion criteria were neoadjuvant therapy and history of malignant tumors. Clinicopathological features, o verall survival (OS), disease-free survival (DFS), and recurr...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Authors: Jiang K, Li L, Xie Y, Xie D, Xiao Q Abstract Stomach adenocarcinoma (STAD) is the most pathological type of gastric cancer. ADAM metallopeptidase with thrombospondin type 1 motif 18 (ADAMTS18) plays an essential role in organ development and tumorigenesis; however, its function in STAD, and its impact on clinical outcome remain unclear. Thus, the present study aimed to investigate the association between ADAMTS18 expression and the prognosis of patients with STAD. Data from 300 patients with STAD in The Cancer Genome Atlas (TCGA) database were analyzed, and the median survival time and overall survival (OS...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Conclusions: Our study suggested that LAPGC patients underwent PG experienced better long-term outcomes than those underwent TG. It also suggested that multimodality treatment of LAPGC, including preoperative chemotherapy followed by TG or postoperative chemotherapy followed by PG, should be considered to achieve better long-term outcomes.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify clinically staged T1N0 patients requiring preoperative chemotherapy. IMPLICATIONS FOR PRACTICE: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify clinically staged T1N0 patients requiring preoperative chemotherapy. PMID: 32969129 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
There are several different types of gastric neoplasm, depending on the cell of origin. The most common gastric neoplasm is adenocarcinoma followed by lymphoma, gastrointestinal stromal tumours (GISTs), carcinoids and other rarer neoplasms. Gastric adenocarcinoma is one of the most common cancers worldwide, especially in the Far East. In the UK, the incidence is lower, but the poor prognosis of late stage disease means the impact on population health is significant. Most patients present with advanced disease at diagnosis.
Source: Surgery (Medicine Publishing) - Category: Surgery Authors: Tags: Oesophagus and stomach Source Type: research
Conclusion: Because the morphology of cancer cells cultured in this 3D culture system is similar to that in living organisms, we called the system a “tissueoid cell culture system.” Coating with collagen IV enables the modification of cell-matrix interactions as well as recapitulation of the in vivo microenvironment.Pathobiology
Source: Pathobiology - Category: Pathology Source Type: research
ConclusionA projected dose and schedule to achieve the targetCtrough was validated in phase 1 of the FIGHT trial which supported selection of the phase 2 dose and schedule for bemarituzumab.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionsMAGEA10 represents a promising predictive marker for early hepatic recurrence after curative gastrectomy for gastric and gastroesophageal junction cancer.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
In conclusion, RES and DDP synergistically inhibited the growth of the gastric adenocarcinoma cell line AGS by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest via activation of the PERK/eIF2α/activating transcription factor 4 (ATF4)/CHOP signaling pathway and caspase‑12 and by inactivating the CDK1‑cyclin B1 complex. These results indicated that RES is a promising adjuvant for DDP during GC chemotherapy. PMID: 32945472 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cancer Therapy | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Pathology